Carlos Gamazo1, Maddi García-Azpíroz1, Juliana De Souza Rebouças1,2, Gabriel Gastaminza3, Marta Ferrer3, Juan M Irache4. 1. Department of Microbiology, University of Navarra, Instituto de Investigación Sanitaria de Navarra (Idisna), C/Irunlarrea, 1; 31080 - Pamplona, Spain. 2. Laboratory of Microbiology & Immunoregulation, Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil. 3. Department of Allergology & Clinical Immunology, Clínica Universidad de Navarra, Navarra, Spain. 4. Department of Pharmacy & Pharmaceutical Technology, University of Navarra, Navarra, Spain.
Abstract
BACKGROUND: Peanut allergy is the most common cause of anaphylaxis and food-related death. However, there is currently no approved immunotherapy treatment. Hence, this warrants the need for relevant and convenient animal models to test for adequate immunotherapies. MATERIALS & METHODS: In this study, we compared three mouse strains: CD1, BALB/c and C57, to select a model of peanut allergy. After that, we conducted then a therapeutic study using an immunogenic peanut extract encapsulated in nanoparticles made with polymer Gantrez® following the solvent displacement method. RESULTS & CONCLUSION: After implementing a dosing schedule with oral commercial peanut butter, the antibody responses, cytokine profiles and, above all, the anaphylaxis induced after a challenge with peanut proteins, showed that the outbred CD1 strain was the most susceptible to peanut sensitization. CD1 sensitized mice were orally immunized with three doses of the nanoparticle formulation capable of protecting them against the severe anaphylactic symptoms induced by the peanut challenge.
BACKGROUND:Peanutallergy is the most common cause of anaphylaxis and food-related death. However, there is currently no approved immunotherapy treatment. Hence, this warrants the need for relevant and convenient animal models to test for adequate immunotherapies. MATERIALS & METHODS: In this study, we compared three mouse strains: CD1, BALB/c and C57, to select a model of peanutallergy. After that, we conducted then a therapeutic study using an immunogenic peanut extract encapsulated in nanoparticles made with polymer Gantrez® following the solvent displacement method. RESULTS & CONCLUSION: After implementing a dosing schedule with oral commercial peanut butter, the antibody responses, cytokine profiles and, above all, the anaphylaxis induced after a challenge with peanut proteins, showed that the outbred CD1 strain was the most susceptible to peanut sensitization. CD1 sensitized mice were orally immunized with three doses of the nanoparticle formulation capable of protecting them against the severe anaphylactic symptoms induced by the peanut challenge.
Authors: Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia Journal: Adv Drug Deliv Rev Date: 2021-12-10 Impact factor: 15.470
Authors: Cristobalina Mayorga; Francisca Palomares; José A Cañas; Natalia Pérez-Sánchez; Rafael Núñez; María José Torres; Francisca Gómez Journal: Foods Date: 2021-05-10